CTRI/2024/01/062101已完成4 期
Spirinolactone versus Bicalatumide in female pattern hair loss; a randomised clinical trial
Abhijeet Kumar Jha1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2024年12月2日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Increase in hair density in 200 patients
研究概览
简要总结
Female Pattern hair loss is characterised by decreased scalp hair density and progressive miniaturization of hair. follicles.
Aims: To compare safety and efficacy of Spirinolactone versus Bicalatumide in Female Pattern Hair Loss [FPHL]
Methods: All eligible female aged18 to 50 years with grade 2-5 Sinclair grade of FPHL will be recruited by randomisation. All treatment naive cases will be included. Global photographic assessment along with trichoscopic images will be captured at each follow up to study any change in hair density and number at each 4 week follow up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 50.00 Year(s)(—)
- 性别
- Female
入选标准
- •Treatment naive Grade 2-5 Female Pattern Hair loss.
排除标准
- •Nursing and pregnant females History of topical minoxidil application History of malignancy History of any SSRI, antihypertensive, potassium supplement Any other hormonal therapy, oral contraceptive pills.
结局指标
主要结局
Increase in hair density in 200 patients
时间窗: 24 weeks
Adverse effects in 200 patients
时间窗: 24 weeks
次要结局
- Increase in hair density in 200patients(Averse effects in 200 patients)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and safety of oral spironolactone combined with 3% topical minoxidil for the treatment of female pattern hair loss in premenopausal womeFemale pattern hair loss (severityLudwig scale 1-2 )female pattern hair lossalopecia in womenandrogenetic AlopeciaalopeciaTCTR20220613005Srinakharinwirot university43
暂停
不适用
Hair Regrowth Effects in Patients with Female Pattern Alopecia by Non-contact Focused UltrasoundFemale Pattern Hair LossjRCTs03222040250
已完成
不适用
Hair loss in women and its relationship with iron and thyroid hormonesCTRI/2018/03/012687Snigdha Hegde100
已完成
4 期
Botulinum toxin as a hair loss treatmentSkin - Dermatological conditionsMetabolic and Endocrine - Other metabolic disordersAndrogenetic alopeciaACTRN12613000821796Paul Nola12
已完成
3 期
Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)AlopeciaNCT01590238The New York Eye & Ear Infirmary15
